Fortress Biotech, Inc. FBIOP 深滬

等待開盤 12-16 09:30:00 美东时间

9.615

+1.907

+24.74%

華盛通

立即下載

最高9.66
今開8.17
成交量 7.03万股
最低 8.10
昨收 7.7079
總市值 3295.16万
52周最高 9.845
市盈率 ^靜 --
換手率 2.05%
52周最低 4.72
委比 -81.82%
總股本 342.71万
歷史最高 20.5506
量比 5.56
振幅 20.24%
歷史最低 -1.5766
每手 1
風險率 0.96%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Journey Medical Corporation announced positive results from a Phase 1 clinical trial of Emrosi, a low-dose oral minocycline for rosacea. The trial met all primary objectives, showing no significant impact on skin, GI tract, or vaginal microbiota, and no safety issues over 16 weeks. Emrosi is FDA-approved for treating inflammatory lesions in adults. The study, published in the Journal of Drugs in Dermatology, supports its long-term use and safety ...

12-10 13:30
Fortress Biotech Q3 EPS $0.11 Beats $(0.42) Estimate, Sales $17.631M Miss $21.018M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.42) by 126.19 percent. This is a 114.47 percent increase over losses of $(0.76) per share

11-14 21:43
Fortress Biotech Q3 Earnings Preview

Fortress Biotech (FBIO) is scheduled to announce Q3 earnings results on Wednesday, November 12th, after market close. The consensus EPS Estimate is -$0.63 and the consensus Revenue Estimate is $21.02M...

11-12 06:35
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Avenue Therapeutics and its subsidiary Baergic Bio have agreed to be acquired by Axsome Therapeutics for up to $82 million in potential milestones and royalties. The acquisition includes global rights to BAER-101, a novel epilepsy treatment, now to be known as AXS-17. Avenue expects to receive approximately 74% of future payments and royalties under the agreement. Baergic shareholders are eligible for up to $79 million in sales-based milestones a...

11-06 12:00
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Journey Medical Corporation will release its third quarter 2025 financial results after U.S. markets close on November 12, 2025. A conference call and audio webcast will be held on the same day at 4:30 p.m. ET. Interested parties can dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international) to join, or access the webcast via the company’s website. A replay will be available for 30 days. The company focuses on selling and marketing FDA-appr...

11-05 13:30
Fortress Biotech Receives FDA Response on CUTX-101

Fortress Biotech ( ($FBIO) ) has shared an announcement. On October 1, 2025, Fo...

10-01 21:19
Fortress Biotech plunges as FDA rejects rare disease drug

Fortress Biotech (NASDAQ:FBIO) fell ~31% in the premarket on Wednesday after the U.S. Food and Drug Administration (FDA) declined to approve CUTX-101, a treatment developed by the company and its Indi...

10-01 20:59
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket

Shares of Ryvyl Inc (NASDAQ:RVYL) rose sharply in pre-market trading after the ...

10-01 17:45
Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

Shares of Docusign Inc (NASDAQ:DOCU) rose sharply in pre-market trading after t...

09-05 17:20
12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers iSpecimen (NASDAQ:ISPC) shares rose 52.4% to $1.0 during Thursday's af...

09-05 05:13

派息除權日	每股總股息	派息日期
2024-06-14	0.20	2024-06-30
2024-05-14	0.20	2024-05-31
2024-04-12	0.20	2024-04-30
2024-03-14	0.20	2024-03-31
2024-02-14	0.20	2024-02-29
2024-01-11	0.20	2024-01-31
2023-12-14	0.20	2023-12-31
2023-11-14	0.20	2023-11-30
2023-10-12	0.20	2023-10-31
2023-09-14	0.20	2023-09-30
2023-08-14	0.20	2023-08-31
2023-07-13	0.20	2023-07-31
2023-06-14	0.20	2023-06-30
2023-05-12	0.20	2023-05-31
2023-04-13	0.20	2023-04-30
2023-03-14	0.20	2023-03-31
2023-02-14	0.20	2023-02-28
2023-01-12	0.20	2023-01-31
2022-12-14	0.20	2022-12-31
2022-11-14	0.20	2022-11-30
2022-10-13	0.20	2022-10-31
2022-09-14	0.20	2022-09-30
2022-08-12	0.20	2022-08-31
2022-07-14	0.20	2022-07-31
2022-06-14	0.20	2022-06-30
2022-05-12	0.20	2022-05-31
2022-04-13	0.20	2022-04-30
2022-03-14	0.20	2022-03-31
2022-02-14	0.20	2022-02-28
2022-01-13	0.20	2022-01-31
2021-12-14	0.20	2021-12-31
2021-11-12	0.20	2021-11-30
2021-10-14	0.20	2021-10-30
2021-09-14	0.20	2021-09-30
2021-08-12	0.20	2021-08-30
2021-07-14	0.20	2021-07-30
2021-06-14	0.20	2021-06-30
2021-05-13	0.20	2021-05-30
2021-04-14	0.20	2021-04-30
2021-03-12	0.20	2021-03-31
2021-02-11	0.20	2021-02-28
2021-01-14	0.20	2021-01-31
2020-12-14	0.20	2020-12-31
2020-11-12	0.20	2020-11-30
2020-10-14	0.20	2020-10-31
2020-09-14	0.20	2020-09-30
2020-08-20	0.20	2020-08-31
2020-07-17	0.20	2020-07-31
2020-06-12	0.59	2020-06-30
2020-03-13	0.59	2020-03-31
2019-12-12	0.59	2019-12-31
2019-09-12	0.59	2019-09-30
2019-06-13	0.59	2019-07-01
2019-03-14	0.59	2019-03-31
2018-12-13	0.59	2018-12-31
2018-09-13	0.59	2018-09-30
2018-06-14	0.59	2018-06-30
2018-03-14	0.59	2018-03-30

公司名稱	Fortress Biotech, Inc.
行業分類	Pharmaceuticals: Major
業務描述	Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech, Inc. FBIOP 深 滬

9.615

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

Fortress Biotech, Inc. FBIOP 深滬